Skip to content

13F-HR filed by EcoR1 Capital, LLC

EcoR1 Capital, LLC filed this 13F-HR for the quarter ended 2015-12-31, filed 2016-02-16, with 31 holding rows worth $318,400,000.

Accession
0001140361-16-052684
Filed
2016-02-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2015

A holdings report, 31 entries on the cover page, a total value of $318,400,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $318,400,000 with VALUE read as thousands by filing date, 13F file number 028-16764. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
FIBROGEN INC31572Q808COM1,216,473$37,066,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock719,000$29,839,000thousands by filing date
JAZZ PHARMACEUTICALS PLCG50871905SHS USD189,200$26,594,000thousands by filing datecall
RETROPHIN INC761299106COM1,224,384$23,618,000thousands by filing date
ARRAY BIOPHARMA INC04269XAA3NOTE 3.000% 6/022,534$21,633,000thousands by filing dateprincipal
KURA ONCOLOGY INC COM50127T109Stock2,450,000$20,580,000thousands by filing date
ASSEMBLY BIOSCIENCES INC045396108COM2,098,302$15,758,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW1,418,700$14,840,000thousands by filing date
VALEANT PHARMACEUTICALS INTE91911K902COM126,500$12,859,000thousands by filing datecall
COLLEGIUM PHARMACEUTICAL INC19459J104COM465,118$12,791,000thousands by filing date
EPIZYME INC29428V104COM698,900$11,196,000thousands by filing date
LAKEFRONT BIOTHERAPEUTICS NV36315X101SPON ADR167,361$10,524,000thousands by filing date
KITE PHARMA INC49803L109COM166,000$10,229,000thousands by filing date
FLEX PHARMA INC33938A105COM795,088$9,899,000thousands by filing date
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK821,531$9,522,000thousands by filing date
NABRIVA THERAPEUTICS AG62957M104SPONSORED ADR838,680$7,931,000thousands by filing date
ATYR PHARMA INC002120103COM790,462$7,770,000thousands by filing date
KINDRED BIOSCIENCES INC COM494577109Stock1,432,765$4,871,000thousands by filing date
RETROPHIN INC761299906CALL244,100$4,709,000thousands by filing datecall
CELLADON CORP15117E107Cmn2,843,170$4,179,000thousands by filing date
OVASCIENCE INC69014Q101COM424,979$4,152,000thousands by filing date
GENVEC INC NEW37246C307cs1,920,913$3,534,000thousands by filing date
CALITHERA BIOSCIENCES INC COM NEW13089P101Stock415,480$3,183,000thousands by filing date
CYTOKINETICS INC23282W905COM NEW284,600$2,977,000thousands by filing datecall
ZAFGEN INC98885E103COM369,000$2,321,000thousands by filing date
FORWARD PHARMA A/S34986J105SPONSORED ADR100,017$1,900,000thousands by filing date
AKARI THERAPEUTICS PLC00972G108ADR100,750$1,461,000thousands by filing date
GILEAD SCIENCES INC375558903COM11,800$1,194,000thousands by filing datecall
NEPHROGENEX INC640667101Cmn588,235$941,000thousands by filing date
QLT INC746927102COMMON STOCK100,000$266,000thousands by filing date
ZAFGEN INC98885E903CALL10,000$63,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001140361-16-052684this filing2016-02-16acceptance time not in the bulk data set